Utilization Trend of Parenteral Antidiabetic Drugs in Type 2 Diabetic Patients Covered by Iran Health Insurance Organization from 2011 to 2030
-
Ali Shojaee
,
Ali Akbari Sari
,
Farshad Farzadfar
,
Majid Davari
,
Rajabali Daroudi
,
Sayyed Masoud Shajari Pour Mousavi
Abstract
Background: Exploring and analyzing the cost of medicines is an important tool for their management and planning. This study aims to analyze the utilization and costs of parenteral anti-diabetic medications during the past decade and predict the future trend of these medications from 2021 to 2031 in people that are covered by Iran Health Insurance Organization (IHIO).
Methods: This study was based on secondary analysis of data routinely reported to IHIO from 2011 to 2019. For each drug, the Defined Daily Dose (DDDs) and DDDs per 1000 inhabitants per day were calculated for the last 9 years according to the WHO protocol. Then a regression analysis was used to predict the utilization trend of each drug for the following 10 years.
Results: The overall utilization of injectable antidiabetic drugs has constantly increased during the last nine years. This increasing trend is estimated to continue during the next decade.
Conclusion: In Iran, the increase in the diabetic population and better access in the future will be the main reasons for the increase in the utilization of various insulins. The increasing trend of utilizing injectable anti-diabetic drugs in Iran might be partly due to new patients and partly because of improvement in patient access to new treatments. This also suggests that, compared to the average in the commonwealth countries, Iranian diabetic patients has faced lack of drug utilization in the past decade that is gradually reducing.
2. Mapa-Tassou C, Katte JC, Mba Maadjhou C, Mbanya JC (2019). Economic Impact of Diabetes in Africa. Curr Diab Rep, 19:5.
3. Education MoHaM (2016) The Project of the Burden of Diseases Center for the Investigation of Non-Communicable Diseases, STEPS.
4. Organisation IDF (2019). International Diabetes Federation Organisation Partnership Annual Report 2019. https://www.idf.org/component/attachments/attachments.html?id=2569&task=download
5. (2020). National Diabetes Statistics Report 2020 Estimates of Diabetes and Its Burden in the United States. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf
6. -IHIO IHIO (2017). Proceedings of the National Conference on Health Insurance; Public coverage and financial resource management. ed.
7. Shajari Pour Mousavi Masoud, Zahra S (2019). FACT SHEET: The Cost of Expensive Diabetes Drugs in the Health Insurance Organization, 2017. In: -NCHIR NCfHIR, Iran Health Insurance Organisation -IHIO, Iran Health Insurance Organisation -IHIO
8. Ebrahimi H, Pishgar F, Yoosefi M, et al (2019). Insulin pen use and diabetes treatment goals: A study from Iran STEPS 2016 survey. PLoS One, 14:e0221462.
9. Elseviers M, Almarsdi AB, Andersen M, Benko R, Bennie M, Eriksson I, Godman B, Krska J, Poluzzi E, Taxis K (2016). Drug utilization research: methods and applications. ed. John Wiley & Sons.
10. Organization WH (2003). Introduction to drug utilization research. ed. World Health Organization.
11. ORGANISATION WH (2020) ATC/DDD Index 2020. https://www.whocc.no/atc_ddd_index/
12. Cheen HH, Lim SH, Huang MC, Bee YM, Wee HL (2014). Adherence to premixed insulin in a prefilled pen compared with a vial/syringe in people with diabetes in Singapore. Clin Ther, 36:1043-53.
13. Parekh W, Hoskins N, Baker-Knight J, et al (2017). The Economic Burden of Insulin-Related Hypoglycemia in Spain. Diabetes Ther, 8:899-913.
14. Soppi A, Heino P, Kurko T, et al (2018). Growth of diabetes drug expenditure decomposed-A nationwide analysis. Health Policy, 122:1326-1332.
15. Organization WH (2018). Guidelines on second-and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus. https://apps.who.int/iris/bitstream/handle/10665/272433/9789241550284-eng.pdf?ua=1
16. Danaei G, Farzadfar F, Kelishadi R, et al (2019). Iran in transition. Lancet, 393:1984-2005.
17. Salman RA, AlSayyad AS, Ludwig C (2019). Type 2 diabetes and healthcare resource utilisation in the Kingdom of Bahrain. BMC Health Serv Res, 19:939.
18. Bang C, Mortensen MB, Lauridsen KG, Bruun JM (2020). Trends in antidiabetic drug utilization and expenditure in Denmark: A 22-year nationwide study. Diabetes Obes Metab, 22:167-172.
19. Sarayani A, Rashidian A, Gholami K (2014). Low utilisation of diabetes medicines in Iran, despite their affordability (2000-2012): a time-series and benchmarking study. BMJ Open, 4:e005859.
20. Chu C-H, Hsu C-C, Lin S-Y, et al (2019). Trends in antidiabetic medical treatment from 2005 to 2014 in Taiwan. J Formos Med Assoc, 118 Suppl 2:S74-S82.
21. Ou HT, Chang KC, Liu YM, Wu JS (2017). Recent trends in the use of antidiabetic medications from 2008 to 2013: A nation-wide population-based study from Taiwan. J Diabetes, 9:256-266.
22. Javanbakht M, Baradaran HR, Mashayekhi A, et al (2011). Cost-of-illness analysis of type 2 diabetes mellitus in Iran. PLoS One, 6:e26864.
23. Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK (2014). Use of antidiabetic drugs in the U.S., 2003-2012. Diabetes Care, 37:1367-74.
24. organisation wh (2016). GLOBAL REPORT ON DIABETES. https://www.who.int/publications-detail-redirect/9789241565257
25. OECD.Stat (2020) Pharmaceutical Market: Pharmaceutical consumption. https://stats.oecd.org/Index.aspx?QueryId=30135
| Files | ||
| Issue | Vol 52 No 5 (2023) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v52i5.12725 | |
| Keywords | ||
| Trend analysis Drug utilizations Defined daily dose Diabetes mellitus | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
